Aptus Pharma ₹44.88 cr issue; AGM on Sept 14

Board clears ₹44.88 crore preferential allotment

Aptus Pharma’s Board of Directors has approved a preferential issue of equity shares that will raise ₹44.88 crore. The company approved the allotment of 16,02,870 equity shares at an issue price of ₹280 per share. The shares are being allotted to 190 investors, as per the final list approved by the board. The decision was taken in a board meeting held on Monday, August 17, 2026. The pricing was finalised based on a valuation report submitted by Registered Valuer CS Amrish N. Gandhi. The valuation report carried a relevant date of August 14, 2026.

The number of allottees in the final approval stands at 190. This was slightly lower than the 192 investors mentioned earlier in the company’s intimation dated August 12, 2026. The preferential issue is a key capital-raising event because it increases the company’s equity base and brings in identified investors at a fixed price. The company has also linked the process to market disclosure timelines through trading window restrictions for designated persons.

Preferential issue terms: shares, price, and investor count

The preferential allotment covers 16,02,870 equity shares priced at ₹280 each. At this price, the total proceeds work out to ₹44.88 crore. The issue is being made to 190 investors, as approved by the board.

Following the allotment of 16,02,870 shares, the combined holding of these investors increases to 8,43,980 shares, which the company stated is 4.50% shareholding post-issue. The post-issue stake figure is an important disclosure because it helps investors understand how much ownership is being consolidated through the preferential route. The company’s communication also indicates that the final list of allottees was adjusted from an earlier set of identified investors.

How the price was finalised

Aptus Pharma stated that the board finalised the preferential issue price during the August 17, 2026 meeting. The price was determined based on a valuation report by Registered Valuer CS Amrish N. Gandhi. The report’s relevant date was August 14, 2026.

The company’s disclosure highlights a formal valuation-led approach to pricing rather than an ad hoc decision. It also indicates the board’s pricing decision was aligned to a specific reference date, which is commonly used for valuation exercises. Beyond naming the valuer and the relevant date, the company did not provide additional valuation assumptions in the information shared.

AGM fixed for September 14, 2026 via VC/OAVM

Alongside the capital-raising update, Aptus Pharma’s board approved the convening of the company’s 16th Annual General Meeting. The AGM is scheduled for Monday, September 14, 2026. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means (VC/OAVM).

The AGM matters for investors because it is the forum where key statutory and shareholder decisions are taken, and it also serves as a structured disclosure event around company governance. The company indicated that the AGM notice and an explanatory statement would be approved in the process. This is consistent with the company’s stated plan to follow the applicable regulatory route for corporate actions.

Trading window closure under insider trading rules

Aptus Pharma stated that, in compliance with SEBI’s Insider Trading Regulations, the trading window for designated persons remains closed until 48 hours after the dissemination of the board meeting outcome to the stock exchanges. Separately, the company also communicated trading window closure periods around earlier board meetings.

For the board meeting scheduled on August 8, 2026 to consider fundraising via preferential allotment, the company had implemented a trading window closure from August 5, 2026 until 48 hours after the board meeting’s outcome is announced. Another disclosure in the provided information states that the trading window has been closed since August 12. These closures are procedural controls intended to restrict trading by designated persons during sensitive periods around material announcements.

The larger expansion fund-raise plan: ₹51 crore mix

Aptus Pharma also disclosed an earlier board-approved enabling proposal to raise funds aggregating up to ₹51 crore for expansion of business operations. This approval was taken during a board meeting held on June 12, 2026, at the corporate office in Rajkot, Gujarat. The company described the plan as a mix of three sources:

• Preferential allotment of securities up to ₹35 crore
• Debt finance or borrowings up to ₹10 crore
• Internal accruals of ₹6 crore

The company also stated that specific details such as the issue price, number of securities, identity of allottees, and record date had not been finalised at that stage and would be approved at a subsequent board meeting. It also noted that implementation of preferential allotment is subject to necessary approvals, including a special resolution from shareholders, and that comprehensive disclosure would be made to stock exchanges under SEBI LODR once final terms are approved.

Key facts at a glance

Earlier corporate actions: bonus issue and approvals

Aptus Pharma previously announced a bonus issue in the ratio of 3 bonus shares for every 2 shares held. The ex-date mentioned was May 12, 2026, and the company stated bonus shares should be credited within three days after the ex-date.

The company also disclosed that shareholders approved two resolutions through postal ballot and remote e-voting, which concluded on April 25, 2026. These resolutions related to an increase in authorised share capital and the bonus issue in the 3:2 ratio. The company stated that voting shareholders supported both proposals unanimously, with 100% of votes cast in favour and no votes against.

Market impact: what the disclosures mean for shareholders

The preferential issue adds fresh equity at a disclosed price of ₹280 per share and raises ₹44.88 crore, which is a concrete inflow of capital. The post-issue stake disclosure of 4.50% for the allottee group provides a direct indicator of ownership concentration through the preferential route. The AGM schedule adds a clear governance milestone, especially since shareholder approvals can be required for certain fundraising actions.

Separately, the ₹51 crore enabling fund-raise plan provides context on the company’s broader expansion financing approach. It splits proposed funding across preferential issuance, borrowings, and internal accruals, which helps investors understand the company’s stated capital structure intent at the planning stage. The presence of trading window closure periods is a compliance indicator tied to the timing of price-sensitive disclosures.

Why this matters: linking the issue to the expansion plan

The ₹44.88 crore preferential issue is a completed board-level approval with explicit terms, including issue price, share count, and investor count. That level of specificity contrasts with the earlier ₹51 crore fundraising plan, which the company described as an enabling resolution where key terms were to be finalised later.

Taken together, these disclosures show a sequence where Aptus Pharma first approved an expansion-oriented fundraising framework and later moved to approve a specific preferential allotment with pricing backed by a registered valuer’s report. The company has also maintained a consistent emphasis on regulatory compliance, citing SEBI regulations for both trading window controls and disclosure obligations.

Conclusion

Aptus Pharma has approved a ₹44.88 crore preferential allotment of 16,02,870 equity shares at ₹280 per share to 190 investors, with the allottee group’s post-issue holding stated at 4.50%. The company has also scheduled its 16th AGM for September 14, 2026 via VC/OAVM and reiterated trading window restrictions tied to board outcomes. Separately, it has an enabling approval in place to raise up to ₹51 crore for business expansion through a mix of preferential allotment, debt, and internal accruals. The next set of investor-relevant details will depend on subsequent filings and any shareholder actions linked to the company’s fundraising and governance calendar.